v3.26.1
Collaboration and License Agreements - Bristol-Myers Squibb Company - Additional Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 25, 2017
USD ($)
Target
Jul. 07, 2014
USD ($)
Term
Target
Jan. 31, 2018
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2023
USD ($)
Feb. 29, 2020
USD ($)
Nov. 30, 2017
USD ($)
Mar. 17, 2017
Target
Dec. 31, 2016
USD ($)
Jan. 31, 2016
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Deferred revenue         $ 28,467 $ 94,063   $ 212,315          
Collaborative Arrangement | Bristol Myers Squibb                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Collaboration target research term   2 years                      
Number of additional collaboration target | Target   2                      
Research terms         Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.                
Extension of research term for each collaboration target   1 year                      
Upfront payment received $ 200,000 $ 50,000                      
Contingent milestone payments receivable                 $ 10,000     $ 15,000 $ 10,000
Number of research targets selected | Target 8                        
Total transaction price   304,700                      
Upfront fee received   250,000                      
Research and development service fees   17,700                      
Milestone payment received     $ 12,000 $ 10,000                  
Milestone payments received           $ 297,000              
Deferred revenue             $ 11,600            
Collaborative Arrangement | Bristol Myers Squibb | Pre Clinical Candidate                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Contingent milestone payments receivable                       $ 2,000  
Collaborative Arrangement | Bristol Myers Squibb | Third And Fourth Target                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Target selection fee   $ 25,000                      
Collaborative Arrangement | Bristol Myers Squibb | New Drug Application for CTLA-4                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Contingent milestone payments receivable                   $ 10,000      
Collaborative Arrangement | Maximum | Bristol Myers Squibb                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Number of oncology target | Target   4                      
Number of collaboration target | Target   2                      
Period of nomination of additional target from effective date   5 years                      
Times of increments for extended collaboration target research time | Term   3                      
Collaborative Arrangement | Maximum | Bristol Myers Squibb | Each Of Two Additional Targets                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Contingent milestone payments receivable   $ 25,000                      
Collaboration and License Agreement | Maximum | Bristol Myers Squibb                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Number of additional collaboration target | Target                     8